Simcere Pharmaceutical Group Limited (02096.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

6.3x

Market Cap

HKD 29.22B

MomentumView details →

1D Return

−1.19%

YTD Return

−2.84%

RSI (14)

46.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

6.3x

Market Cap

HKD 29.22B

RSI (14)

46.1

MomentumView details →

1D Return

−1.19%

YTD Return

−2.84%

ProfitabilityView details →

Gross Margin

82.02%

Net Margin

15.46%

EBITDA Margin

22.42%

ROE (TTM)

25.87%

ROA (TTM)

15.77%

Asset Turnover

1.04x

GrowthView details →

Revenue YoY

+18.16%

EPS YoY

+23.62%

FCF YoY

+338.87%

Revenue CAGR 3Y

+6.96%

EPS CAGR 3Y

+14.47%

EBITDA YoY

+81.56%

EarningsView details →

EPS (Actual)

HKD 0.44

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

1.32%

Capital & dividendView details →

Debt/Equity

0.13x

Current Ratio

1.90x

Quick Ratio

1.74x

Div Yield

1.78%

Div Rate

HKD 0.21

Div Growth 1Y

+18.36%

Financials snapshotView financials →

Revenue (TTM)

15.77B

Net Income (TTM)

2.44B

Op. CF (TTM)

—

Next earningsMar 25, 2027 →

Latest newsMore news →

China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.4d ago

Simcere Pharmaceutical announced that Zhou Yunshu stepped down as CEO and was appointed President, while founder Ren Jinsheng resumed the role of CEO, effective August 20, 2026.15d ago

Similar companies

Royalty Pharma plcRPRX Insmed IncorporatedINSM 泽璟制药-U688266.SH InnoCare Pharma Limited09969.HK BioNTech SEBNTX Incyte CorporationINCY Find similar companies →

Latest newsMore news →

China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.4d ago Simcere Pharmaceutical announced that Zhou Yunshu stepped down as CEO and was appointed President, while founder Ren Jinsheng resumed the role of CEO, effective August 20, 2026.15d ago